| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2019: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2018: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2017: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Outline of Final Research Achievements |
In this study, we adressed to 1; identify MMPs that are reduced in expression during EMT-induced formation of type 4D highly invasive oral cancer cells and cancer-associated fibroblasts; 2; investigate their degradative activity against PD-L1. 3; identify cleavage sites. 4; among MMPs that degrade PD-L1, we identified MMPs that suppress T-cell immune tolerance. 5; in addition, the tumor immune activation effects of MMP in the cancer microenvironment were verified using 4D type high invasion oral cancer cell which stably expresses MMP which suppresses this immune tolerance and selective MMP synthetic inhibitors.
We verified whether type 4D highly invasive oral cancer cells at the invasive front were transformed into minimally invasive cancer by tumor immunity activated with MMPs using a murine oral cancer invasive metastatic model.
|
